GLP-1 & Obesity— Companies & Signals
The GLP-1 & Obesity investment theme focuses on companies developing novel therapeutics, particularly GLP-1 receptor agonists, to address the growing global epidemic of obesity and related metabolic diseases. This market represents a significant opportunity due to the unmet medical need and the potential for substantial revenue growth from effective, long-term weight management solutions. 49 public companies above the $50M floor. Last 90 days: 24 red 8-Ks, 0 insider cluster-buys, 5 running hot in the press.
49
Companies
24
Red 8-Ks · 90d
0
Insider clusters
5
🔥 Media-hot
Companies in GLP-1 & Obesity
Refine in search →| # | Ticker | Company | Sector | Mkt cap | 1D | 5D | Volume | Heat | Signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics, Inc | Healthcare | $7.1B | -0.2% | +5.7% | 740K | — | red 8-K |
| 2 | VANI | Vivani Medical, Inc. | Healthcare | $94.9M | +0.8% | +7.1% | 47K | — | |
| 3 | BIOA | BioAge Labs, Inc. | Healthcare | $801.9M | +5.0% | +16.2% | 769K | — | |
| 4 | GPCR | Structure Therapeutics Inc. | Healthcare | $3.1B | +4.0% | +13.6% | 779K | — | red 8-K |
| 5 | WVE | Wave Life Sciences Ltd. | Healthcare | $1.1B | -2.6% | -7.9% | 2.7M | — | |
| 6 | VTVT | vTv Therapeutics Inc. | Healthcare | $129.0M | +3.4% | +6.9% | 80K | — | |
| 7 | SRRK | Scholar Rock Holding Corp | Healthcare | $5.3B | +0.4% | +11.7% | 2.1M | — | |
| 8 | IBIO | iBio, Inc. | Healthcare | $84.0M | +3.6% | -0.6% | 1.1M | — | red 8-K |
| 9 | ALT | Altimmune, Inc. | Healthcare | $507.6M | +4.3% | +0.3% | 3.6M | — | |
| 10 | BHVN | Biohaven Ltd. | Healthcare | $1.7B | -5.6% | -3.5% | 3.5M | ⚡ | |
| 11 | DRIO | DarioHealth Corp. | Healthcare | $51.6M | -3.3% | +7.3% | 13K | — | red 8-K |
| 12 | ENTX | Entera Bio Ltd. | Healthcare | $60.6M | +1.2% | +11.5% | 474K | — | |
| 13 | SGMT | Sagimet Biosciences Inc. | Healthcare | $400.2M | +10.3% | +9.7% | 1.4M | — | red 8-K |
| 14 | MED | MEDIFAST INC | Consumer Staples | $132.2M | +1.8% | -2.9% | 212K | — | red 8-K |
| 15 | OMDA | Omada Health, Inc. | Healthcare | $1.0B | +3.7% | +20.5% | 1.8M | — | |
| 16 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Healthcare | $151.7M | +2.8% | +8.1% | 418K | 🔥 | red 8-K |
| 17 | GYRE | GYRE THERAPEUTICS, INC. | Healthcare | $575.4M | +2.5% | +5.2% | 80K | — | red 8-K |
| 18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Healthcare | $11.1B | +2.9% | +2.8% | 447K | — | red 8-K |
| 19 | PROK | PROKIDNEY CORP. | Healthcare | $336.5M | +3.3% | +3.9% | 1.4M | — | |
| 20 | LLY | ELI LILLY & Co | Healthcare | $1010.3B | +1.8% | +11.6% | 3.7M | 🔥 | |
| 21 | AIRS | Airsculpt Technologies, Inc. | Healthcare | $377.4M | -1.1% | -4.6% | 430K | — | |
| 22 | SMPL | Simply Good Foods Co | Consumer Staples | $1.1B | +0.6% | +10.8% | 3.8M | — | red 8-K |
| 23 | HIMS | Hims & Hers Health, Inc. | Healthcare | $6.2B | -1.6% | -0.5% | 14.1M | — | |
| 24 | PRQR | ProQR Therapeutics N.V. | Healthcare | $151.7M | +19.6% | -2.7% | 2.6M | — | |
| 25 | HRMY | Harmony Biosciences Holdings, Inc. | Healthcare | $2.0B | -0.4% | +5.7% | 830K | — | red 8-K |
| 26 | APYX | Apyx Medical Corp | Healthcare | $196.4M | +4.2% | +17.0% | 271K | — | |
| 27 | WW | WW INTERNATIONAL, INC. | Consumer Discretionary | $185.5M | +2.6% | -10.9% | 129K | — | red 8-K |
| 28 | IMUX | IMMUNIC, INC. | Healthcare | $188.8M | +0.7% | +4.5% | 358K | — | red 8-K |
| 29 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Healthcare | $6.1B | +0.2% | +8.5% | 828K | ⚡ | red 8-K |
| 30 | LFVN | Lifevantage Corp | Healthcare | $114.2M | -6.3% | +2.0% | 189K | — | red 8-K |
| 31 | ARCO | Arcos Dorados Holdings Inc. | Consumer Discretionary | $1.9B | -2.5% | -2.2% | 1.6M | — | |
| 32 | NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $16.1B | +0.9% | +5.2% | 1.4M | — | red 8-K |
| 33 | LXRX | LEXICON PHARMACEUTICALS, INC. | Healthcare | $852.9M | +3.5% | +22.8% | 4.6M | — | |
| 34 | AZN | ASTRAZENECA PLC | Healthcare | $277.2B | +1.4% | +8.2% | 1.6M | 🔥 | |
| 35 | DMAC | DiaMedica Therapeutics Inc. | Healthcare | $304.4M | +10.2% | +22.6% | 395K | — | |
| 36 | KLRA | Kailera Therapeutics, Inc. | Healthcare | $2.4B | +4.0% | -5.3% | 582K | — | |
| 37 | CTNM | Contineum Therapeutics, Inc. | Healthcare | $444.2M | +5.7% | +29.1% | 449K | — | |
| 38 | TNXP | Tonix Pharmaceuticals Holding Corp. | Healthcare | $180.9M | -3.6% | +4.5% | 526K | — | red 8-K |
| 39 | COYA | Coya Therapeutics, Inc. | Healthcare | $111.2M | +10.4% | +14.7% | 293K | — | red 8-K |
| 40 | VNDA | Vanda Pharmaceuticals Inc. | Healthcare | $353.0M | +2.2% | +2.3% | 874K | — | red 8-K |
| 41 | CRNX | Crinetics Pharmaceuticals, Inc. | Healthcare | $3.6B | +0.7% | +4.4% | 884K | — | red 8-K |
| 42 | MGTX | MeiraGTx Holdings plc | Healthcare | $888.1M | +3.5% | +9.2% | 683K | — | |
| 43 | PODD | INSULET CORP | Healthcare | $10.4B | -0.3% | +13.5% | 1.6M | 🔥 | red 8-K |
| 44 | KROS | Keros Therapeutics, Inc. | Healthcare | $200.9M | -0.6% | -0.5% | 353K | — | red 8-K |
| 45 | IMMX | Immix Biopharma, Inc. | Healthcare | $601.6M | +5.1% | +11.6% | 1.9M | — | |
| 46 | CVS | CVS HEALTH Corp | Consumer Staples | $130.1B | -0.7% | +2.3% | 4.8M | 🔥 | red 8-K |
| 47 | AMLX | Amylyx Pharmaceuticals, Inc. | Healthcare | $1.6B | +5.1% | +14.9% | 2.4M | — | |
| 48 | ZBIO | Zenas BioPharma, Inc. | Healthcare | $1.3B | -1.2% | +22.8% | 1.7M | — | red 8-K |
| 49 | DXR | DAXOR CORP | Other | $54.1M | +0.9% | +6.4% | 3K | — |
Membership is matched by keyword from companies’ SEC business descriptions (10-K Item 1) — deterministic, not AI inference. May not be exhaustive; not investment advice.